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Coronavirus Disease 2019 (COVID-19), emerged in Wuhan, China, in December 2019. As of 10 March 2020, COVID-19 cases have been report-
ed in 114 countries from all Continents except Antarcti-
ca, with accumulative 80 932 cases in China and 29 432 
in other countries [1]. The transmission potential of 
COVID-19, determined by reproduction number (R0) of 3.28, is much higher that of severe acute res-
piratory syndrome (SARS) [2]. Bold measures taken by China have effectively curbed the rapid spread of 
this new respiratory disease source and changed the dangerous process of rapid spread of the epidemic 
[3]. The world is not yet ready to organize and implement the measures that have been proved to be ef-
ficient and effective by China to block or minimize the spread of new coronavirus [3]. The crude case-fa-
tality rate (CFR) of COVID-19 is reported to be 2.3% in all patients [4], while higher to be 61.5% in crit-
ically ill patients [5]. Therefore, early screening and quarantining mild or asymptomatic cases and early 
diagnosis of sever patients for intensive treatment are urgent to avoid the pandemic of COVID-19.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) testing was recommended to confirm COV-
ID-19 cases by China medical authority [6], however the total positive rate of RT-PCR for throat swab 
samples was about 30% to 60% at initial presentation. Chest Computed Tomography (CT), a routine im-
aging method, has also been applied to diagnose COVID-19 infection [7]. A study on the correlation of 
chest CT and RT-PCR testing of COVID-19 based on 1014 cases demonstrated that the sensitivity of chest 
CT imaging for COVID-19 was 97% 
(580/601), and the specificity was 25% 
(105/413), with RT-PCR as a diagnosis cri-
terion [8]. As a new emerging infectious dis-
ease, there is no gold criteria for the diagno-
sis of COVID-19. Our current study showed 
that if chest CT was taken as a reference of 
diagnosis standard, the sensitivity of RT-PCR 
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Neither chest CT nor RT-PCR testing alone is ac-
curate enough for the diagnosis of COVID-19 in-
fection.
Parallel tests with CT and RT-PCT are recom-
mended to be applied in the screening of CO-
VID-19 for isolation, while series test with CT 
or RT-PCT should be used in COVID-19 diag-
nosis confirmation for treatment.
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Photo: Parallel or serial test (from the authors’ own collection, used with permission).
Table 1. The performance of RT-PCR for COVID-19 infection 
with chest CT result as reference
CT RT-PCR SenSiTiviTy 
 (95 % Ci)
SPeCifiCiTy 
(95% Ci)positive negative
Positive 580 308 65% 
 (62%-68%)
83% 
(76%-89%)Negative 21 105
CT – computed tomography, RT-PCR – reverse transcriptase 
polymerase chain reaction, CI – confidence interval
testing for COVID-19 was 65% (580/888), and the specificity 
is 83% (105/126) (Table 1). Thus, if both sensitivity and spec-
ificity were taken into account simultaneously, neither chest 
CT nor RT-PCR testing alone is accurate enough for the diag-
nosis of COVID-19 infection.
Considering that asymptomatic cases are also of higher trans-
mission potential, sensitivity should be first considered for the 
screening purpose of COVID-19 infection. When confirma-
tion for intensive treatment, specificity should be first consid-
ered to avoid false treatment. Parallel tests and serial test are needed to increase both sensitivity and spec-
ificity. Parallel tests perform RT-PCR and CT imaging at the same time and the results are cross-referenced 
to make the diagnosis [9]. Serial test employs as a secondary screening test which is performed only if the 
result of initial screening test is positive [9]. For screening purposes, parallel tests, ie, positive in either 
RT-PCR or chest CT is used to clinically diagnose COVID-19, can improve sensitivity and decrease false 
negative cases. For therapy purposes serial tests should be used to improve specificity and decrease false 
positive cases. Consequently, we recommend that parallel tests are used in screening, while series tests 
should be used for diagnosis confirmation of COVID-19. The proposed strategic approach for screening 
and diagnosis confirmation of COVID-19 infection might also be of reference significance for other coun-
tries or other emerging infectious disease.
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